EBS Stock Cash Flow Statements

Emergent BioSolutions Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Free Cash Flow

Capital Expenditure

Emergent BioSolutions Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2013-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31

operating activities
net income	-49,500,000	-266,700,000	-261,300,000	-183,000,000	-88,000,000	-75,700,000	-56,400,000	-3,700,000	189,300,000	-32,700,000	4,600,000	69,700,000	185,400,000	39,500,000	92,700,000	-12,500,000	46,900,000	43,200,000	-9,600,000	-26,000,000	-8,805,000	26,900,000	-137,000	12,523,000	-23,173,000	23,888,000	11,944,000	9,434,000	1,918,000	3,661,000	-539,000	13,251,000	10,172,000	1,455,000	10,386,000	1,817,000	7,024,000	2,845,000	-4,960,000	-2,690,000
adjustments to reconcile net income to net cash from operating activities:
share-based compensation expense						11,200,000	12,300,000	9,900,000		10,400,000	11,400,000	10,500,000				6,600,000		6,100,000	8,100,000	6,800,000
depreciation and amortization	29,600,000	28,000,000	32,900,000	34,600,000	35,600,000	32,300,000	44,500,000	30,900,000	29,200,000	32,700,000	33,200,000	28,700,000	28,900,000	28,800,000	28,600,000	28,200,000	27,900,000	27,700,000	28,500,000	26,600,000	4,163,000	2,429,000	2,412,000	2,279,000	2,235,000	1,970,000	1,374,000	1,350,000	1,296,000	1,322,000	1,170,000	1,245,000	1,262,000	1,417,000	1,285,000	1,181,000	1,081,000	1,265,000	1,134,000	1,198,000
change in fair value of contingent obligations	600,000	-2,300,000	400,000	1,500,000
amortization of deferred financing costs	5,700,000	5,700,000	8,900,000	1,000,000	1,000,000	1,100,000	1,000,000	1,000,000	1,000,000	1,100,000	1,000,000	1,000,000	1,100,000	900,000	800,000	700,000	800,000	700,000	800,000	700,000
deferred income taxes	-5,200,000	6,500,000	-1,800,000	-8,400,000	-42,000,000	20,400,000	700,000	1,900,000	46,300,000	3,800,000	-1,500,000	-1,700,000	2,000,000	-700,000	500,000	-4,200,000	4,600,000	-4,400,000	10,100,000	-11,400,000		8,251,000	8,808,000	250,000	2,879,000	6,413,000	1,079,000	2,618,000	819,000	368,000	5,896,000	407,000	933,000	1,821,000	822,000	-1,135,000	498,000	121,000	6,897,000	2,400,000
gain on sale of travel health business	0	700,000
goodwill impairment	0
impairment of long-lived assets	0	0																				300,000	483,000
write off of contract asset and liability
other	4,100,000	-600,000	9,200,000	300,000	-6,600,000	10,800,000	1,600,000	600,000	-3,100,000	3,100,000	-1,500,000	3,500,000	-5,800,000	-500,000			-900,000	-2,200,000	3,000,000	-100,000	6,000	332,000	17,000
changes in operating assets and liabilities:
accounts receivable	36,900,000	72,100,000	-132,400,000	1,800,000	38,500,000	-21,500,000	4,000,000	93,700,000	66,500,000	-80,000,000	-76,800,000	42,100,000	-25,600,000	62,500,000	-96,100,000	108,200,000	10,400,000	-63,200,000	-97,000,000	141,600,000	33,079,000	-25,205,000	-1,731,000	-35,287,000	27,350,000	-27,841,000	37,828,000	-12,360,000	21,467,000	-29,159,000	29,686,000	18,737,000	-49,281,000	-10,785,000	8,381,000	-933,000	-2,701,000	-22,616,000	-15,462,000	39,396,000
inventories	25,600,000	-1,200,000	5,800,000	-29,600,000	60,300,000	-36,700,000	-25,400,000	-50,100,000	14,000,000	21,700,000	20,200,000	-99,900,000	-35,600,000	-33,900,000	11,900,000	-25,600,000	7,700,000	1,700,000	-20,900,000	-5,200,000	-6,987,000	3,318,000	-717,000	4,901,000	-9,441,000	4,598,000	-204,000	-35,000	-3,560,000	2,295,000	-1,774,000	110,000	5,576,000	-2,212,000	1,363,000	-89,000	-1,893,000	3,263,000	-2,001,000	-2,163,000
prepaid expenses and other assets	30,000,000	-500,000	-13,300,000	-4,500,000	9,300,000	-9,800,000	-2,800,000	-16,600,000	30,100,000	-52,400,000	7,600,000	-10,000,000	32,600,000	-44,900,000	-1,600,000	-15,300,000	9,100,000	8,400,000	-28,300,000	-16,600,000	-246,000	390,000	-1,287,000	549,000	1,008,000	141,000	-953,000	-417,000	576,000	-1,443,000	-2,158,000	-8,000	2,379,000	-797,000	-943,000	-1,401,000	-405,000	-86,000	-731,000	-292,000
accounts payable	-7,100,000	6,800,000	-20,100,000	31,000,000	-5,000,000	-1,400,000	7,100,000	-14,700,000	-6,000,000	-4,500,000	-12,100,000	20,100,000	9,200,000	25,100,000	1,100,000	-15,600,000	14,000,000	-40,100,000	38,400,000	4,200,000	-4,196,000	2,391,000	885,000	-313,000	-453,000	-2,367,000	1,839,000	3,036,000	1,115,000	-5,706,000	5,521,000	-960,000	-189,000	708,000	-3,158,000	3,750,000	-1,757,000	2,722,000	-675,000	-2,735,000
accrued expenses and other liabilities	-25,500,000	-16,400,000	900,000	-14,700,000	31,300,000	-15,200,000	-26,300,000	-56,500,000	10,100,000	36,100,000	-15,400,000	-40,000,000									21,000	64,000	-185,000	20,000	6,000	133,000	-27,000	-475,000	146,000	-117,000	-52,000	223,000	-120,000	-1,399,000	1,365,000	-219,000	-270,000	171,000	749,000	-223,000
long-term incentive plan accrual
accrued compensation	-9,600,000	12,600,000	11,900,000	-25,300,000	5,800,000	8,400,000	18,100,000	-32,200,000	15,100,000	10,300,000	8,000,000	-29,400,000	7,300,000	17,900,000	11,500,000	-14,900,000	6,600,000	11,100,000	7,800,000	-21,300,000	-10,982,000	5,937,000	912,000	136,000	-10,288,000	7,384,000	2,169,000	2,234,000	-5,580,000	763,000	4,201,000	1,676,000	-3,094,000	2,325,000	1,740,000	723,000	-2,910,000	6,000	2,887,000	-2,467,000
income taxes receivable and payable	-12,700,000	-17,700,000	1,300,000	12,900,000
contract liabilities	4,100,000	9,500,000	700,000	-8,400,000	5,400,000	1,500,000	4,700,000	-2,000,000	-12,300,000	-19,900,000	-9,000,000	9,400,000	20,200,000	-38,100,000	28,600,000	500,000
net cash from operating activities	32,100,000	60,000,000	-114,400,000	-184,000,000	92,800,000	-74,000,000	-15,600,000	-37,300,000	329,000,000	16,700,000	-29,700,000	5,100,000	245,100,000	105,200,000	127,900,000	57,800,000	122,100,000	-3,100,000	-35,800,000	104,800,000	-4,626,000	38,564,000	4,836,000	-6,752,000	-22,055,000	24,178,000	54,172,000	3,792,000	17,401,000	-23,287,000	33,336,000	45,908,000	-25,446,000	-11,939,000	19,943,000	4,341,000	-5,028,000	-10,108,000	-28,373,000	14,786,000
capex	-14,900,000	-11,100,000	-12,600,000	-7,300,000	-24,200,000	-25,200,000	-38,100,000	-18,900,000	-47,300,000	-66,300,000	-800,000	-23,600,000	-36,000,000	-52,800,000	-25,600,000	-16,900,000	-36,100,000	-15,300,000	-14,100,000	-21,400,000	-7,679,000	-19,873,000	-17,358,000	-8,363,000	-8,432,000	-8,059,000	-5,411,000	-3,601,000	-5,030,000	-18,911,000	-5,282,000	-4,339,000	-4,755,000	-4,349,000	-3,921,000	-5,612,000	-6,294,000	-6,090,000	-11,833,000	-10,979,000
free cash flows	17,200,000	48,900,000	-127,000,000	-191,300,000	68,600,000	-99,200,000	-53,700,000	-56,200,000	281,700,000	-49,600,000	-30,500,000	-18,500,000	209,100,000	52,400,000	102,300,000	40,900,000	86,000,000	-18,400,000	-49,900,000	83,400,000	-12,305,000	18,691,000	-12,522,000	-15,115,000	-30,487,000	16,119,000	48,761,000	191,000	12,371,000	-42,198,000	28,054,000	41,569,000	-30,201,000	-16,288,000	16,022,000	-1,271,000	-11,322,000	-16,198,000	-40,206,000	3,807,000
investing activities
purchases of property, plant and equipment	-11,400,000	-12,600,000	-12,500,000	-15,100,000	-23,600,000	-27,900,000	-32,100,000	-32,200,000	-46,700,000	-55,200,000											-7,679,000	-19,873,000	-17,358,000	-8,363,000	-8,432,000	-8,059,000	-5,411,000	-3,601,000	-5,030,000	-18,911,000	-5,282,000	-4,339,000	-4,755,000	-4,349,000	-3,921,000	-5,612,000	-6,931,000	-8,854,000	-10,853,000	-16,490,000
royalty settlement payment
milestone payment from prior asset acquisition	0													0
asset acquisitions					0
proceeds from sale of travel health business	0	0
net cash from investing activities	-11,400,000	-18,900,000	257,700,000	-15,100,000																	-7,679,000	-18,340,000	-15,809,000	-7,073,000	-12,741,000	-9,414,000	-5,411,000	-3,601,000	-5,030,000	-18,911,000	-5,282,000	-4,339,000	-4,755,000	-4,349,000	-3,921,000	-12,112,000	-10,431,000	-13,854,000	-10,853,000	-16,490,000
financing activities
purchases of treasury stock					-200,000	0	-24,400,000	-57,500,000
principal payments on convertible senior notes									0	0	0	-10,600,000
proceeds from revolving credit facility					360,000,000												0	0	100,000,000	30,000,000
principal payments on revolving credit facility	-12,000,000	-39,000,000											0	-353,000,000	0	-20,000,000	-10,000,000	-15,000,000	0	-80,000,000
principal payments on term loan facility	-3,900,000	-3,900,000	-148,400,000	-8,400,000	-8,500,000	-8,400,000	-8,400,000	-8,500,000	-8,400,000	-5,600,000	-5,700,000	-5,600,000	-5,700,000	-2,800,000	-2,800,000	-2,800,000	-2,900,000	-2,800,000	-2,800,000	-2,800,000
proceeds from stock-based compensation activity	500,000	0
taxes paid for stock-based compensation activity	-100,000	-100,000	-200,000	-2,100,000
proceeds from at-the-market sale of stock, net of commissions and expenses	200,000	0
contingent consideration payments									1,300,000	-1,400,000	-400,000	-700,000	-600,000	-1,100,000	-400,000	-700,000	-46,700,000	-2,700,000	-500,000	-500,000
net cash from financing activities:	4,700,000	-43,000,000	-486,900,000	-10,500,000	353,100,000	229,300,000	-30,700,000	-70,500,000	-110,000,000	-5,000,000	-3,800,000	-22,200,000		87,100,000	4,700,000	-20,000,000		-19,700,000	100,100,000	-58,400,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	-1,500,000	1,100,000	-600,000	-200,000	1,100,000	-1,000,000	700,000	-300,000	0	-200,000	200,000	-300,000		-400,000	-200,000	100,000
net change in cash, cash equivalents and restricted cash	23,900,000	-800,000			401,600,000	-117,300,000	-77,700,000	-140,300,000	172,300,000	-43,700,000	-100,300,000	-73,500,000
cash, cash equivalents and restricted cash, beginning of period	0	0	0	642,600,000
cash, cash equivalents and restricted cash, end of period	23,900,000	-800,000	-341,600,000	430,200,000
supplemental cash flow disclosures:
cash paid for interest	11,800,000	17,700,000	17,200,000	21,600,000
cash paid for income taxes	14,500,000	11,400,000	10,200,000	16,700,000
non-cash investing and financing activities:
purchases of property, plant and equipment unpaid at period end	-3,500,000	1,500,000	-100,000	7,800,000	-600,000	2,700,000	-6,000,000	13,300,000	-600,000	-11,100,000	-800,000	32,500,000		-7,100,000	9,500,000	7,300,000																					637,000	2,764,000	-980,000	5,511,000
purchases of treasury stock unpaid at period end
gain on extinguishment of debt
stock-based compensation expense		4,000,000	8,300,000	6,800,000									10,000,000	10,000,000							2,976,000	2,828,000	2,761,000	2,709,000	2,441,000	1,857,000	1,843,000	1,841,000	1,522,000	1,362,000	1,395,000	1,390,000	860,000	777,000	747,000	756,000	230,000	735,000	631,000	529,000
long-term incentive plan expense		1,300,000
supplemental disclosure of cash flow information:
supplemental information on non-cash investing and financing activities:
net change in cash, cash equivalents and restricted cash excluding cash classified within assets held for sale				-209,800,000
add: net change in cash, classified within current assets held for sale				-2,600,000
reconciliation of cash and cash equivalents and restricted cash at march 31, 2023 and december 31, 2022:
cash and cash equivalents				430,200,000	401,700,000	-117,200,000	-77,700,000	435,800,000	172,300,000	-43,700,000	-100,300,000	547,800,000	206,300,000	146,200,000	87,300,000	181,500,000
cash and cash equivalents included in assets held for sale				2,600,000
total				432,800,000	401,600,000	-117,300,000	-77,700,000	436,000,000	172,300,000	-43,700,000	-100,300,000	548,000,000	206,300,000	146,200,000	87,300,000	181,700,000
impairments
proceeds from senior unsecured notes													0
debt issuance costs													0
reconciliation of cash and cash equivalents and restricted cash:
restricted cash						-100,000	0	200,000	0	0	0	200,000	0	0	0	200,000
cash flows used in operating activities:
adjustment for prior period lease receivables
change in fair value of contingent consideration						600,000	1,300,000	500,000		900,000	600,000	1,100,000	400,000	30,200,000	500,000	600,000	12,400,000	6,900,000	3,800,000	1,700,000
cash flows used in investing activities:
net cash from investing activities:						-271,600,000	-32,100,000	-32,200,000		-55,200,000	-67,000,000	-56,100,000	-36,000,000	-45,700,000	-45,100,000	-24,200,000	-36,100,000	-15,300,000	-24,100,000	-21,400,000
cash flows from financing activities:
proceeds from share-based compensation activity						0	2,500,000	500,000		2,500,000	3,100,000	6,900,000
taxes paid for share-based compensation activity						-300,000	-400,000	-5,000,000		-500,000	-800,000	-12,200,000	-1,000,000	-1,100,000
cash, cash equivalents and restricted cash at beginning of period						0	0	576,300,000	0	0	0	621,500,000		0	0	168,000,000		0	0	112,400,000
cash, cash equivalents and restricted cash at end of period						-117,300,000	-77,700,000	436,000,000	172,300,000	-43,700,000	-100,300,000	548,000,000		146,200,000	87,300,000	181,700,000		-38,200,000	40,200,000	137,400,000
cash paid during the period for interest						11,900,000	3,100,000	11,700,000		11,800,000	3,100,000	12,400,000		2,400,000	4,200,000	7,400,000																						699,000	874,000	644,000
cash paid during the period for income taxes						3,900,000	15,200,000	4,800,000		7,300,000	48,800,000	1,500,000		75,100,000	8,600,000	3,600,000																						369,000	1,460,000	12,500,000
reconciliation of cash and cash equivalents and restricted cash at september 30, 2022 and december 31, 2021:
cash flows used in financing activities:
reconciliation of cash and cash equivalents and restricted cash at june 30, 2022 and december 31, 2021:
cash flows from operating activities:
reconciliation of cash and cash equivalents and restricted cash at march 31, 2022 and december 31, 2021:
cash flows from investing activities:
cash paid during the year for interest
cash paid during the year for income taxes
impairment of ipr&d
reconciliation of cash and cash equivalent and restricted cash at september 30, 2021 and december 31, 2020:
adjustments to reconcile to net income to net cash from operating activities:
reconciliation of cash and cash equivalent and restricted cash at june 30, 2021 and december 31, 2020:
purchases of property, plant and equipment and other												-56,100,000	-36,000,000	-45,700,000	-35,100,000	-24,200,000	-36,100,000	-15,300,000	-14,100,000	-21,400,000
reconciliation of cash and cash equivalent and restricted cash at march 31, 2021 and december 31, 2020:
adjustments to reconcile to net cash from operating activities:
impairment of ipr&d intangible asset													0
milestone payment from asset acquisition																	0
business acquisitions, net of cash acquired
proceeds from sale of assets
proceeds from term loan facility
receipts and payments of restricted cash
purchase of treasury stock
net cash from financing activities																					995,000	-2,454,000	14,347,000	-1,037,000	3,395,000	2,963,000	807,000	-14,002,000	874,000	26,692,000	-11,870,000	-166,000	188,000	2,892,000	4,484,000	-700,000	2,292,000	14,411,000	5,872,000	-6,899,000
effect of exchange rate changes on cash and cash equivalents																					-118,000	785,000	-122,000	31,000	-693,000	63,000	-532,000	-380,000	215,000	-347,000	85,000	-275,000	-80,000	181,000	175,000	-269,000	184,000	-163,000	-311,000	-170,000
net change in cash and cash equivalents and restricted cash
cash and cash equivalents and restricted cash at beginning of year
cash and cash equivalents and restricted cash at end of year
issuance of common stock to acquire adapt pharma
purchases of property, plant and equipment unpaid at year end
accrued expenses														-20,600,000	23,900,000	1,100,000		-1,700,000	5,200,000	1,700,000
proceeds from exercise of stock options														3,500,000
net increase in cash, cash equivalents and restricted cash														146,200,000	87,300,000	13,700,000		-38,200,000	40,200,000	25,000,000
reconciliation of cash and cash equivalent and restricted cash at september 30, 2020 and december 31, 2019:
reconciliation of cash and cash equivalent and restricted cash at june 30, 2020 and december 31, 2019:
proceeds from issuance of common stock upon exercise of stock options																9,100,000
taxes paid on behalf of employees for equity activity																-5,600,000	-800,000	-300,000	-300,000	-6,000,000
reconciliation of cash and cash equivalent and restricted cash at march 31, 2020 and december 31, 2019:
share-based compensation
income taxes																					-7,918,000	17,182,000	-7,352,000	6,830,000	-15,238,000	4,478,000	-4,418,000	-3,755,000	-2,459,000	-1,064,000	-10,680,000	3,620,000	4,599,000	-1,947,000	-1,210,000	228,000	-3,785,000	1,801,000	-9,935,000	-17,686,000
deferred revenue																			14,300,000	2,100,000	197,000	-5,778,000	-1,149,000	-1,450,000	-2,486,000	-821,000	12,000	0	-14,000	0	-223,000			-2,441,000	-408,000	-144,000	-150,000	-335,000	-199,000	-481,000
payment of notes payable to aptevo
net increase in cash and cash equivalents and restricted cash
cash flows from provided by financing activities:
issuances of stock under share-based benefit plans																		1,100,000	3,700,000	900,000
stock-based compensation
impairment and abandonment of long-lived assets
excess tax benefits from stock-based compensation																					-1,608,000	-698,000	284,000	-1,747,000	-39,000	-623,000	-368,000	-333,000	-376,000	-297,000	-1,042,000	-317,000	-196,000					0
changes in operating assets and liabilities, net of business acquisitions:
proceeds from long-term debt obligations
principal payments on long-term indebtedness																					-1,117,000
distribution to aptevo
net decrease in cash and cash equivalents																																	-30,093,000		20,681,000	-8,740,000	-12,983,000	-9,714,000	-33,665,000	-8,773,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
impairment of intangible assets
bad debt expense
benefit from chargebacks
acquisitions
issuance of common stock upon exercise of stock options
payments of notes payable
net increase in cash and cash equivalents																					-11,428,000	18,555,000	3,252,000	-14,831,000	-32,094,000	17,790,000	49,036,000	-14,191,000	13,460,000	-15,853,000	16,269,000
write off of debt issuance costs
acquisitions, net of acquired cash
proceeds from convertible debenture, net of bank fees
contingent obligation payments
non-cash development expenses from joint venture																					190,000					3,754,000	2,056,000	168,000	17,000	1,189,000	1,938,000	2,455,000	1,633,000
impairment of in-process research and development
proceeds from maturity of investments																						500,000	1,500,000
purchase of investments																						1,033,000	49,000	-960,000	-4,309,000
acquisition of healthcare protective products division
proceeds from borrowings on long-term indebtedness
issuance of common stock subject to exercise of stock options																					504,000	1,190,000	141,000	4,497,000	4,198,000	3,179,000	1,272,000	1,531,000	1,253,000	271,000	3,059,000	483,000	651,000	2,771,000	406,000			55,000	1,529,000	890,000
principal payments on long-term indebtedness and line of credit																						-563,000	-6,808,000	-7,281,000	-842,000	-837,000	-833,000	-15,866,000	-15,755,000	-1,052,000	-15,971,000	-15,966,000	-15,659,000
restricted cash deposit
current and deferred income taxes																					-4,516,000
change in fair value of contingent value rights																						-1,104,000	-83,000
contingent value right payment
cash and cash equivalents at beginning of period																					141,666,000		0	0	169,019,000		0	0	102,924,000		0	0	91,473,000		0	0	105,730,000	0	0	76,418,000
cash and cash equivalents at end of period																					130,238,000		3,252,000	-14,831,000	136,925,000		49,036,000	-14,191,000	116,384,000		16,269,000	41,128,000	61,380,000		20,681,000	-8,740,000	92,747,000	-9,714,000	-33,665,000	67,645,000
benefit from impairment of accrued interest on note receivable
acquisition of trubion pharmaceuticals, inc., net of cash acquired
repayment of note receivable
proceeds from borrowings on long-term indebtedness and line of credit																						6,224,000							15,000,000				15,000,000
issuance of common stock to acquire trubion pharmaceuticals, inc.
non-cash development expenses from variable interest entities																							915,000
proceeds from borrowing on line of credit
non-cash development expenses from joint ventures																									2,550,000
gain on disposal of property and equipment																									13,000				-34,000					47,000	1,000
benefit from impairment of long-lived assets																										189,000	0	481,000	548,000	3,510,000	0
benefit from fair value of contingent value rights																									581,000
proceed from maturities of investments
repayment/(issuance) of note receivable
restricted cash release																																		-8,000
(gain) loss on disposal of property, plant and equipment
proceeds from borrowings on line of credit																											0
(gain) loss on disposal of property and equipment
issuance of note receivable
gain on disposal of property, plant and equipment																															-3,000
proceeds from line of credit
loss on disposal of property and equipment																																	25,000				10,000
adjustments to reconcile net income to net cash from operating activities
purchased in-process research and development
acquisitions, net of cash received
proceeds from borrowings on long term indebtedness and line of credit																																		15,000,000	15,000,000
issuance of common stock in initial public offering
redemption of class b common stock
principal payments on long term indebtedness, notes payable to employees, and line of credit
minority interest in subsidiary
issuance of a note receivable
principal payments on long term indebtedness and line of credit
principal payments on long term indebtedness and line of credits
issuance of notes receivable																																					-3,500,000
proceeds from borrowings on long term indebtedness and lines of credit																																					15,000,000
principal payments on long term indebtedness, notes payable to employees, and lines of credits																																					-12,708,000			-9,386,000
restricted cash deposits
principal payments on long term indebtedness, notes payable to employees, and lines of credit																																						-977,000
proceeds from excess tax benefits																																								1,597,000
non-cash gain on settlement
other obligations
excess tax benefit from stock based compensation
proceeds from investment maturities
proceeds from notes payable to employees
repayments on product supply and royalty obligations
payment of dividend
issuance of common stock to acquire microscience limited

We provide you with 20 years of cash flow statements for Emergent BioSolutions stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Emergent BioSolutions stock. Explore the full financial landscape of Emergent BioSolutions stock with our expertly curated income statements.

The information provided in this report about Emergent BioSolutions stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.